^
    BIOMARKER:

    ALK rearrangement

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor




    Show legend

    Include preclinical:
    Non Small Cell Lung Cancer
    Lung Non-Squamous Non-Small Cell Cancer
    Lung Adenocarcinoma
    Lung Cancer
    Renal Cell Carcinoma
    Neuroendocrine Tumor
    Solid Tumor
    Lung Non-Small Cell Squamous Cancer
    Non-Hodgkin’s Lymphoma
    Sarcoma
    Small Cell Lung Cancer
    Tyrosine kinase inhibitor
    ALK inhibitor
    PD-L1 inhibitor
    Immunotherapy
    alectinib
    crizotinib
    ceritinib
    bevacizumab + atezolizumab
    alectinib + capmatinib
    lorlatinib
    brigatinib
    nivolumab
    bevacizumab + alectinib
    ceritinib + ribociclib
    durvalumab
    camrelizumab + rivoceranib
    crizotinib + lorlatinib
    AUY922
    bevacizumab + crizotinib
    IPI-504
    ipilimumab
    iruplinalkib
    atezolizumab
    bevacizumab
    BMS-722782
    alectinib + YHO-1701
    gilteritinib